Directorate Change (8795H)

TIDMMDST

RNS Number : 8795H

Medicsight Plc

06 June 2011

6 June 2011

Medicsight PLC

("Medicsight" or "the Company")

Appointment of independent non executive director

Medicsight PLC (AIM: MDST), an industry leader in the development of Computer-

Aided Detection (CAD) and image analysis software, announces that with effect from 1 June 2011 Ralph Stephen Harris, has joined the Board of the Company as an independent non executive director.

Further to the announcement on 18 February 2011, Peter Venton will continue to act as interim non-executive Chairman although is expected that Mr Harris will take over the role of Chairman in due course with Mr Venton to continue on the board as a senior non-executive director.

Mr Ralph Stephen Harris, B.Pharm.; F.R. Pharm. S. (known as Steve Harris) 68 years of age, does not hold any interest in the share capital of the Company. Mr Harris has the current and past directorships or partner roles in the companies or partnerships set out below. There is no other information in relation to Mr Harris required to be disclosed pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.

This announcement sets out the disclosures required pursuant to Schedule 2, paragraph (g) of the AIM Rules for Companies in respect of this appointment.

Mr Stephen Harris

 
 Current Directorships            Past Directorships 
-------------------------------  ------------------------------- 
 Proteome Sciences plc            Phynova Group plc 
 Cyprotex plc                     Advanced Medical Solutions 
                                   Group plc 
 Aquapharm Biodiscovery Limited   Myotec Therapeutics Limited 
 Ocelus Limited                   Sinclair Pharma plc 
 Andersen Piquet Limited          SkyePharma plc 
 Electrophoretics Limited         Premier Research Group plc 
 Symbiotic Consortia Limited      Northwest Biotherapeutics 
                                   Inc 
                                  Reliance GeneMedix plc 
                                  Microscience Limited 
                                  Gensia Limited 
                                  PolyMASC plc 
                                  Ultrasis UK Limited 
                                  Pharmaceuticals Profiles 
                                   Limited 
                                  Conve plc 
                                  Evans Medical Pensions Limited 
 

- ENDS -

For further information:

 
 Medicsight plc 
 Allan Rowley, CEO                 Tel: [phone] 
                                   www.medicsight.com 
                                    follow us on twitter 
                                    @Medicsight 
 Daniel Stewart & Co Plc 
  Nominated Adviser & Broker 
 Noelle Greenaway / Oliver Rigby   Tel: [phone] 
                                    6550 
                                   www.danielstewart.co.uk 
 

Media enquiries:

 
 Abchurch 
 Simone Elviss / Quincy Allan / Adam   Tel: [phone] 
  Michael / Julian Bosdet               7728 
 [e-mail]      www.abchurch-group.com 
 

Notes to editors

Medicsight plc is a UK-headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's CAD software has been developed using a large and population diverse database of verified patient CT scan data. Medicsight's ColonCAD(TM) software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 2000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This can be critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome. In addition to supporting individual radiologists CAD also has the potential to help standardise CT interpretation across both individuals and institutions thereby supporting population based screening programmes.

About Medicsight's CAD software

Medicsight's ColonCAD(TM) software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOADKNDQABKDDAK